Summary:
- The European Union has approved Sanofi's Wayrilz (fostamatinib) as the first Bruton's tyrosine kinase (BTK) inhibitor to treat immune thrombocytopenia (ITP), a rare autoimmune disorder that causes low platelet levels.
- ITP can lead to easy bruising, frequent nosebleeds, and an increased risk of internal bleeding. Wayrilz works by inhibiting the BTK enzyme, which plays a role in the destruction of platelets in ITP patients.
- This approval provides a new treatment option for ITP patients in the EU, offering an alternative to traditional therapies like corticosteroids and immunoglobulins. Wayrilz has the potential to improve the quality of life for those living with this rare and chronic condition.